FP802 (8 μM, 24–72 h) effectively disrupts the NMDAR/TRPM4 complex and provides neuroprotection in cell models, but it does not directly promote or inhibit neurite growth [1]. FP802 (10 μM, 30 min) exhibits strong neuroprotective effects, resisting glutamate (20 μM)-mediated toxicity (IC50 = 8.7 µM) and restoring NMDA-inhibited early gene expression to physiological levels [2]. FP802 did not show antagonistic activity against NMDAR in HEK293 cells (IC50 of GluN1/GluN2A and GluN1/GluN2B were both > 250 mM) [2]. FP802 (30 min) was able to dose-dependently block NMDA-induced postmitotic death of neurons in sporadic ALS disease-specific induced pluripotent stem cell (iPSC)-derived forebrain organoids [2].

FP802 (10 and 40 mg/kg, epidermal, once daily for 4 months) improved cognitive function, prevented metastructural damage and reduced amyloid pathology in 5xFAD mice[1]. FP802 (40 mg/kg, subcutaneous injection, once daily for 4 weeks starting from week 15) safely prevented ALS motor neuron shortening and prolonged its survival through the NMDAR/TRPM4 complex[2].

Real Time qPCR[1]
Cell Types: mouse cortical neurons
Tested Concentrations: 10 μM
Incubation Duration: 30 min
Experimental Results: Eliminated the transcriptional shut-off induced by eNMDARs and boosted the NMDA bath application-induced expression of the immediate-early genes (IEGs) Atf3, Arc, Bdnf, cFos, Inhibin beta A, and Npas4 to reach levels that were comparable to those achieved by Bicuculline induced action potential bursting.

Animal/Disease Models: 5xFAD transgenic mice and wild-type littermates[1]
Doses: 10 and 40 mg/kg
Route of Administration: p.o., daily for 4 months
Experimental Results: Showed no apparent adverse effects on the liver, kidney, or heart. Reduced the complex formation of GluN2B with TRPM4 in the 5xFAD mice at both 10 and 40 mg/kg. Reduced complex formation of GluN2A with TRPM4 at 40 mg/kg. Significantly decreased the interaction between NMDAR and TRPM4 without affecting the total protein levels of GluN2A, GluN2B, or TRPM4. Led to a significant increase in the time 5xFAD mice spent in the target quadrant and the frequency with which they crossed the platform's prior location at the dose of 40 mg/kg, compared to vehicle. Increased the time 5xFAD mice spent exploring the novel object in the Novel Object Recognition (NOR) test and the displaced object in the Novel Location Recognition (NLR) test relative to vehicle treatment. Prevented the shift of mitochondrial morphologies from normal to pathological phenotypes in both CA1 and CA3. Effectively preserved dendritic trees in 5xFAD mice as compared to controls, as demonstrated by increased total dendritic length and numbers of crossings in the Sholl analysis. Prevented the increase in the density of 'apparent orphaned synapses' in both stratum oriens (CA1 basal dendrites) and stratum radiatum (CA1 apical dendrites) of 5xFAD mice. Prevented the loss of excitatory and inhibitory synapses and the associated structural deterioration of postsynaptic densities (PSD) in the basal and apical dendrites of CA1 neurons, thereby preserving synaptic integrity in 5xFAD mice. Led to a 25-40% reduction in Aβ plaque load, significantly limiting plaque development without completely preventing its formation.

---

Animal/Disease Models: Male SOD1G93A transgenic mice and wild-type littermates[2]
Doses: 40 mg/kg
Route of Administration: s.c., daily from ~week 15 for 4 weeks
Experimental Results: Disrupted he interaction of TRPM4 with the NMDAR subunit GluN2B in mice spinal cord. Significantly better neurological scores and less body weight loss than vehicle-treated controls. Significantly improved motor performance (increased total distance traveled and rearing frequency in the open field). Significantly extended the lifespan of SOD1G93A mice (survival median increased from 151 to 164 days). Preserved larger soma sizes of lumbar spinal motor neurons compared to the control group at week 19. Significantly reduced serum NfL levels while showing no effect on spinal microglial response or EAAT2 expression. Showed no adverse effects on liver, kidney, heart, or blood counts.

[1]. https://pubmed.ncbi.nlm.nih.gov/40858778/

[2]. https://pubmed.ncbi.nlm.nih.gov/38325382/

C11H17CLN2

212.72

61694-81-3

FP802 dihydrochloride

Typically exists as solids at room temperature

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

---

Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).

View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

---

Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).

View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

---

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

---

 (Please use freshly prepared in vivo formulations for optimal results.)